The synthesis of novel compounds starting from 2-amino-8-(2-chlorobenzylidene)-4-(2-chlorophenyl)-5,6,7,8- tetrahydro-4H-chromene-3-carbonitrile 2 has been studied. Diarylidene cyclohexanone reacts with malononitrile to afford compound 2. Compound 2 reacts with benzoyl chloride to afford compound 3. N-(8-(2-chlorobenzylidene)- 4-(2-chlorophenyl)-3-cyano-5,6,7,8-tetrahydro-4H-chromen-2-yl)benzamide 3 reacts with acetic anhydride to afford compound 4. Compound 2 reacts with acetic anhydride to afford 9-(2-chlorobenzylidene)-5-(2-chlorophenyl)-2- methyl-3,5,6,7,8,9-hexahydro-4H-chromeno[2,3-d]pyrimidin-4-one 5. Chromene derivative 2 reacts with formic acid to give compound 6. Compounds 46 react with phosphorus oxychloride to give compounds 7ac. Chromeno[2,3-d] pyrimidine derivatives 7ac react with hydrazine hydrate to afford compounds 8ac. Chromeno[2,3-d]pyrimidine derivatives 8a,b react with xylose and glucose to give compounds 9ad. Chromeno[2,3-d]pyrimidine derivatives 9ad react with acetic anhydride to give compounds 10ad. Screening of most of the synthesized compounds against A-549, CaCo-2, and HT-29 cell lines were done. 2-Amino-8-(2-chlorobenzylidene)-4-(2-chlorophenyl)-5,6,7,8- tetrahydro-4H-chromene-3-carbonitrile 2 gives high cytotoxic activity against A-549 and HT-29 cancer cell lines as compared to doxorubicin as the reference drug.
Key words: Tetrahydrochromenes, Chromene(2,3-d)pyrimidines, Chromenotriazolopyrimidine, pyrimidines, triazolopyrimidine, cytotoxic activity.
|